Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3950908 | 0.91 | HTR2A (0.68) | HTR2AHTR2C | |
| SCHEMBL3945349 | 0.86 | HTR2A (0.67) | HTR2AHTR2C | |
| SCHEMBL3954826 | 0.85 | HTR2A (0.72) | HTR2AHTR2C | |
| SCHEMBL3949327 | 0.85 | HTR2A (0.70) | HTR2AHTR2C | |
| SCHEMBL3945596 | 0.84 | HTR2A (0.70) | HTR2AHTR2C | |
| SCHEMBL130675 | 0.83 | HTR2A (0.78) | HTR2AHTR2C | |
| SCHEMBL19413127 | 0.81 | HTR2A (0.86) | HTR2AHTR2C | |
| SCHEMBL3944946 | 0.81 | HTR2A (0.62) | HTR2AHTR2C | |
| SCHEMBL3950888 | 0.80 | HTR2A (0.64) | HTR2AHTR2C | |
| SCHEMBL3947342 | 0.80 | HTR2A (0.77) | HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268443-B1 | 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE | SMITHKLINE BEECHAM PLC (GB) | 2009-07-29 | — | — | EP | claimed |
| US-20030114674-A1 | 2-Hydroxy-mutilin carbamate derivatives for antibacterial use | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-06-19 | — | — | US | claimed |
| EP-2051978-A2 | ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2007136875-A2 | ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114674-A1 | 2-Hydroxy-mutilin carbamate derivatives for antibacterial use | MSH6, MSH2, PMS2 | HTR2A 2769/4885HTR2C 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.